Fig. 3

Effects of taxifolin treatment on CBF and CVR in Tg-SwDI mice. Taxifolin restored CBF reduction and impaired CVR caused by vascular amyloid-β in Tg-SwDI mice. a Representative images showing resting CBF measured by laser speckle flowmetry in vehicle-treated WT (left), vehicle-treated (middle), and taxifolin-treated Tg-SwDI (right), mice at 12 months of age receiving taxifolin or vehicle for 11 months. b A histogram showing CBF (n = 7–13 for each group). c Representative images of CBF levels monitored by laser speckle flowmetry before (left column; baseline) and 1 min (middle column) and 5 min (right column) after hypercapnia in vehicle-treated WT (upper row), vehicle-treated (middle row) and taxifolin-treated, Tg-SwDI mice (lower row) at 12 months of age receiving taxifolin or vehicle for 11 months. d Temporal profiles of %increase in CBF in WT (black open circle) and Tg-SwDI mice treated with vehicle (red-filled triangle) or taxifolin (blue-filled square) (n = 4–6 for each group). Error bars indicate ± SD (b) and ± SE (d). *p < 0.05 and #p < 0.05 in WT versus vehicle-treated Tg-SwDI mice and in vehicle-treated versus taxifolin-treated Tg-SwDI mice